Zenotech today asked Japanese drug firm Daiichi Sankyo, whose open offer to buy 20 per cent more in the bio-technology firm hit legal hurdles, to go in for independent valuation to determine open offer price.     

"I have written to Daiichi Sankyo that instead of getting into legal hurdles they should appoint an independent investment banker to find out the valuation of the company and based on that valuation open offer prices should be announced," Zenotech CEO Jayram Chirugurupati said over telephone.     

Click here for Cloud Computing

Also Read   Related Stories News Now - Madras HC halts Daiichi's open offer for Zenotech - Sun Pharma, Forest settle US suit on Lexapro - Glenmark Generics launches hypertension drug in US - Aurobindo Pharma gets USFDA approval for CVS drug - Zenotech moves CLB to oust Ranbaxy-appointed board members - Zenotech moves CLB to remove Ranbaxy-appointed board members

Also Read   Related Stories News Now - Weekly: Indices surge 3% led by rate sensitives - Wall St Week Ahead: Stocks may strain to hold 9-month highs - Iran-Pakistan gas pipeline a bad idea: US - FII-TO-FII: Pantaloon traded at 7% premium - Civic polls: Saffron alliance retains Mumbai, Thane More

In February, Daiichi Sankyo had announced it would launch an open offer at a price of Rs 113 per share for Zenotech to acquire 68.85 lakh shares or a 20 per cent stake in it.     

Ranbaxy, which had about 45 per cent stake in Zenotech, was acquired by Daiichi Sankyo, and the stake was transferred to the Japanese firm. Under the Securities and Exchange Board of India (SEBI) rules, Daiichi had to launch an open offer to acquire additional 20 per cent stake in Zenotech.     

Daiichi had said it would pay Rs 78.23 crore, at Rs 113.62 a share, to Zenotech shareholders in the open offer, which was scheduled to begin on July 15 and close on August 3.     

However, the offer ran into controversy as the pharma firm complained to SEBI against Daiichi for allegedly not honouring a commitment to make the offer at Rs 160 per share.

When contacted a Daiichi Sankyo spokesperson said that the company is currently evaluating the order and has postponed the launch of the open offer.    

Asked whether the company has any plans to revise the open offer price, the spokesperson said, "The price of open offer was determined as per the SEBI guidelines and it has no plans to change it."

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Weekly: Indices surge 3% led by rate sensitives - Wall St Week Ahead: Stocks may strain to hold 9-month highs - Iran-Pakistan gas pipeline a bad idea: US - FII-TO-FII: Pantaloon traded at 7% premium - Civic polls: Saffron alliance retains Mumbai, Thane

Tags : pharmaceutical | Zenotech | Daiichi Sankyo | Ranbaxy | Sebi | open offer |   Read Business news in  Advertisements -  Now property search gets more exciting than ever before! -  High Growth Business Opportunities in Africa - Register to explore -  Medium-sized businesses are the engines of a smarter planet. -  Save over Rs.3000 with IndianOil Citibank Card -  India's No. 1 Property Site. Click here to know more.. -  Get 5% cashback on telephone bills with Citi -  Diseases earlier, Saving Costs, Extending Lives. Know More.. -  Enjoy the journey as much as the destination. click to know more.. -  Exim Bank Conclave on India - Africa Project Partnership. Know more.. -  Creating Wealth made simple the SIP way. Know more.. -  Only Developer to give a guarantee on time space & rate. -  Office 365 for professionals and small businesses. -  Buy Your Property with Our Triple Guarantee in India. -  Improve Patient Care & Experience. Click here to know more -  Win a Business Class Ticket to Europe..Know more.. -   Introduce a New Automotive Luxury Car.. know more